I have taken a small position back into PainChek recently.
I met Phillip Daffas and David Allsopp at the recent Techknow Conference in Sydney last week. The company is making great progress and well capitalised.
The valuation is a lot more attractive than it was a year ago.
The recent acquisition by Pfizer of ResApp puts the spotlight on digital health and the importance of high quality data.
